Compare TVTX & PJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVTX | PJT |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.4B |
| IPO Year | 2013 | 2015 |
| Metric | TVTX | PJT |
|---|---|---|
| Price | $51.58 | $136.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | $75.21 | ★ $161.11 |
| AVG Volume (30 Days) | ★ 1.6M | 396.4K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,713,671,000.00 |
| Revenue This Year | $47.65 | $8.41 |
| Revenue Next Year | $49.39 | $13.42 |
| P/E Ratio | ★ N/A | $23.03 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $22.59 | $127.73 |
| 52 Week High | $68.73 | $195.62 |
| Indicator | TVTX | PJT |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 34.96 |
| Support Level | $41.75 | $127.73 |
| Resistance Level | $59.93 | $163.37 |
| Average True Range (ATR) | 2.20 | 4.34 |
| MACD | -0.38 | 0.47 |
| Stochastic Oscillator | 1.49 | 30.88 |
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.